City
Epaper

Oxford-AstraZeneca Covid-19 vaccine shows strong immune response in older adults

By IANS | Updated: November 19, 2020 17:05 IST

Covid-19 vaccine being developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University produced a strong immune response in older ...

Open in App

Covid-19 vaccine being developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University produced a strong immune response in older adults, raising hopes that it can protect the age groups most at risk from the virus.

The study, published in The Lancet medical journal, suggest that those aged over 70 who are at higher risk of serious illness and death from Covid-19 could build robust immunity to the novel Coronavirus.

"We were pleased to see that our vaccine was not only well-tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers," Dr Maheshi Ramasamy, an investigator at the Oxford Vaccine Group, was quoted as saying to the BBC.

"The next step will be to see if this translates into protection from the disease itself," Ramasamy added.

According to the researchers, two weeks after the second dose, more than 99 per cent of participants had neutralising antibody responses. These included people of all ages.

The T-cell response - another measure of how well the immune system responds - peaked two weeks after the first dose of the vaccine, regardless of age.

"The robust antibody and T-cell responses were seen in older people in our study are encouraging. The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults," Ramasamy said.

"We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure," she added.

According to the study, older adults were also less likely to experience side-effects, which were usually mild. And there were no serious safety issues relating to the vaccine, called ChAdOx1 nCov-2019.

Three vaccines - Pfizer-BioNTech, Sputnik and Moderna have already reported good preliminary data from phase three trials, with one suggesting 94 per cent of over-65s could be protected from Covid-19.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Oxford university-astra zenecaCoronavirus VaccineCovid-19Oxford University
Open in App

Related Stories

MaharashtraMaharashtra Reports 12 New COVID-19 Cases, One Death in 24 Hours

NationalKarnataka: Over 20 Die of Heart Attacks in 40 Days in Hassan District; Probe Ordered

MumbaiMumbai: BMC Confirms Zero New COVID-19 Cases in Mumbai, No Concerning Variants Detected

MaharashtraMaharashtra COVID-19 Update: State Reports 13 New Cases, One Death

MaharashtraMaharashtra Reports 24 New COVID-19 Cases, No Fresh Deaths

Health Realted Stories

HealthAurobindo Pharma’s Q1 net profit falls 10 pc to Rs 824 crore

HealthBangladesh: Two more people die of dengue, death toll rises to 86 in 2025

HealthIRDAI slaps Rs 5 crore penalty on Policybazaar for various violations

HealthGovt extends special registration drive for pregnant, lactating women till Aug 15

HealthRani Kapur requests UK authorities to conduct in-depth probe into her son’s death